The Latest

This Week in HIV Research: Looking Forward, Looking Back Img

This Week in HIV Research: Looking Forward, Looking Back

In our final installment of 2017, we intermingle forward-looking research with some retrospective analysis. We begin our four-study tour by joining researchers in Tennessee for an exercise in HIV outbreak prediction.

Lopinavir/Ritonavir Pellets for Children Tentatively Approved by the FDA Img

Lopinavir/Ritonavir Pellets for Children Tentatively Approved by the FDA

On May 21, the U.S. Food and Drug Administration tentatively approved lopinavir/ritonavir 40/10-mg pellets for infants and young children less than 3 years old.

Promo Image

U.S. Jury Rejects Glaxo Antitrust Claim vs. Abbott

In Oakland, Calif., on Wednesday, a 10-member federal jury rejected GlaxoSmithKline's (GSK) antitrust claim that Abbott Laboratories had quadrupled the price of its HIV drug Norvir in order to preserve the sales growth of its HIV drug Kaletra.


Promo Image

U.S. Warns Against Abbott HIV Drug in Premature Babies

On Tuesday, the Food and Drug Administration advised against using Kaletra (lopinavir/ritonavir) oral solution in premature babies, which can cause severe or possibly fatal health problems, and in all babies younger than 14 days. There is no safe, es...

Promo Image

Indian Government Rejects Abbott's Patent Application for Second-Line ARV

India's patent office "has rejected American drug maker Abbott Laboratories' patent application for an HIV combination drug, allowing low-cost local drug makers to make and sell their generic versions in India and other countries where the medicine i...

Promo Image

FDA Probes Risks of HIV, Prostate, Other Drugs

The Food and Drug Administration's latest Adverse Event Reporting System update indicates the agency is investigating potential safety issues associated with the HIV drug Kaletra and several other medications. FDA said it is tracking reports of liver...

Promo Image

Once-Daily Kaletra Dosing Approved for Treatment-Experienced Adults

On April 27, 2010, FDA approved a new dosing regimen for Kaletra (lopinavir/ritonavir) tablets and oral solution. Kaletra can be administered once daily (800/200 mg) in patients with less than three lopinavir resistance associated substitutions. Once...

Promo Image

Kaletra (Lopinavir/Ritonavir) Package Insert Revision Regarding Drug-Drug Interaction Information

On January 29, 2009, FDA approved revisions to the Kaletra (lopinavir/ritonavir) package insert to include drug-drug interaction information for concurrent Kaletra administration with inhaled medicines such as salmeterol or salmeterol in combination ...

Promo Image

Labeling Changes for Kaletra Reflecting New QT/QTC Interval and PR Interval Prolongation Information

FDA approved, on April 6, 2009, changes to the product label for Kaletra (lopinavir/ritonavir) Tablets and Oral Solution, reflecting new WARNINGS and PRECAUTIONS regarding QT/QTC interval and PR interval prolongation information.

QT/QTC interval and...

Promo Image

Abbott Drug Pricing Condemned by AIDS Advocates in International Protests

Chicago -- As part of an ongoing multinational campaign to lower drug prices and improve access to lifesaving AIDS treatments globally, AIDS advocates from three countries -- Colombia, Mexico and the United States -- are holding simultaneous protests...